Printer Friendly

IMMUCOR TO ENTER JOINT DEVELOPMENT AGREEMENT FOR BLOOD BANK AUTOMATION

 IMMUCOR TO ENTER JOINT DEVELOPMENT AGREEMENT
 FOR BLOOD BANK AUTOMATION
 NORCROSS, Ga., April 6 /PRNewswire/ -- Immucor, Inc. (NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today it has reached agreement with Bio-Tek Instruments, Inc. to begin joint development of a fully automated, hospital blood bank instrument.
 The instrument will be marketed by Immucor and utilize Immucor's proprietary Capture(R) product technology. Bio-Tek will be responsible for manufacturing and service.
 Initially, Immucor will invest $1.0 million in Bio-Tek common stock. These funds will be used by Bio-Tek for working capital and to complete an engineering feasibility study of the design stage. If the feasibility study is successful, Immucor will fund 85 percent of the research and development effort, and Bio-Tek will fund the balance. The project is expected to take approximately two years to complete, with a research and development cost to Immucor of $2.5 million.
 Commenting on the development project, Edward L. Gallup, president of Immucor, Inc., said: "We believe Bio-Tek is an excellent choice for us to realize the full potential of our solid phase technology -- a fully automated, or 'walk away' instrument designed for the hospital blood bank. We will be combining the engineering expertise of Bio-Tek with our Capture products reagent technology."
 Gallup also noted Immucor believes the potential worldwide market for such an instrument-reagent system is $200 million. The instruments would utilize Immucor's patented, solid phase tests for performing routine patient testing, which are currently performed manually by blood bank technologists.
 Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. Founded in 1968, privately held Bio-Tek is a leader in the design and manufacturing of medical instrumentation and related software.
 -0- 4/6/92
 /CONTACT: Richard J. Still, senior vice president-Finance of Immucor, 404-441-2051/
 (BLUD) CO: Immucor, Inc.; Bio-Tek Instruments, Inc. ST: Georgia IN: MTC SU: JVN


BR-EA -- AT002 -- 5177 04/06/92 07:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:353
Previous Article:AMSOUTH BANCORPORATION REPORTS PRELIMINARY FIRST QUARTER EARNINGS
Next Article:IMED AND MCGAW SIGN PACT ON DISPOSABLE DEVICE


Related Articles
IMMUCOR TO CONTINUE BLOOD BANK AUTOMATION DEVELOPMENT PROJECT
IMMUCOR AND DYNATECH ANNOUNCE JOINT DEVELOPMENT OF ABS HV SYSTEM
Immucor, Inc. Announces ABS2000 Analyzer Cleared for Sale Into Italy
Immucor Enters Agreement with IBG Systems
Immucor Inc. Announces Agreement with Mediware.
Immucor Achieves 1,000,000 Test Per Month Milestone.
Immucor Announces Expanded Agreement with Japanese Distributor.
Immucor Announces Agreement With Novation.
Immucor Places 100th Blood Automation System in North America Company Reaches Milestone Ahead of Schedule.
Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters